For HER2-low breast cancer, the HER2/neu-derived nelipepimut-S (NeuVax) combined with GM-CSF yielded 100% 5-year disease-free survival in phase II trials [96], now under phase III evaluation (PRESENT trial, NCT04373148). Here, ERBB2 is linked to breast cancer.